RT Journal Article
SR Electronic
T1 Evaluation of hematological parameters and thrombocytopenia following Pfizer-BioNTech (BNT162b2) SARS-CoV-2 vaccination
JF Saudi Medical Journal
JO Saudi Med J
FD Prince Sultan Military Medical City
SP 567
OP 571
DO 10.15537/smj.2022.43.6.20220135
VO 43
IS 6
A1 Abdullah Algaissi
A1 Edrous Alamer
A1 Mohammed Jeraiby
A1 Abeer Alomaish
A1 Omer Elrhima
A1 Sultan Qumayi
A1 Naaif A. Qasir
A1 Halima Areeshi
A1 Asma Masmali
A1 Abdulaziz Alhazmi
YR 2022
UL http://smj.org.sa/content/43/6/567.abstract
AB Objectives: To evaluate hematological parameters and thrombotic profiles of healthy individuals who received Pfizer-BioNTech (BNT162b2) vaccines in Saudi Arabia.Methods: Hematological parameters and the incidence of anti-platelet factor-4 (anti/PF-4) antibodies were evaluated in 40 participants who were eligible for COVID-19 vaccination in Saudi Arabia (above 18 years old) at Jazan University Hospital. These parameters were assessed at 2 different timepoints; at day 0 (the day of receiving the first dose of Pfizer- BioNTech (BNT162b2) and prior to vaccination) and 14-21 days after receiving the vaccine.Results: Among the participants, 38 (80%) were men, while 12 (20%) were women, with a mean age of 27 years. A total of 15% of the participants reported previous infection with SARS-CoV-2 and 3 patients had a history of diabetes mellitus and hypertension. Hematological parameters results in those vaccines showed no significant changes between the 2 timepoints, such as, day 0 (just before receiving vaccination) and 14 to 21 days post vaccination. Further, anti/PF4 antibodies were negative for all participants following vaccination.Conclusion: Our data showed that the incidence of hematological abnormalities or induction of anti/PF4 antibodies following Pfizer-BioNTech (BNT162b2) vaccination is not common, which is consistent with several previous reports. However, larger studies with more participants evaluated at different timepoints following vaccination are warranted to exclude potential transient hematological abnormalities.